[go: up one dir, main page]

AR042472A1 - Preparaciones de liberacion controlada que comprenden tramadol y topiramato - Google Patents

Preparaciones de liberacion controlada que comprenden tramadol y topiramato

Info

Publication number
AR042472A1
AR042472A1 ARP030104634A ARP030104634A AR042472A1 AR 042472 A1 AR042472 A1 AR 042472A1 AR P030104634 A ARP030104634 A AR P030104634A AR P030104634 A ARP030104634 A AR P030104634A AR 042472 A1 AR042472 A1 AR 042472A1
Authority
AR
Argentina
Prior art keywords
hours
tramadol
preparation
substrate
effective amount
Prior art date
Application number
ARP030104634A
Other languages
English (en)
Original Assignee
Cilag Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag Ag filed Critical Cilag Ag
Publication of AR042472A1 publication Critical patent/AR042472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación farmacéutica oral adecuada para la dosificación cada 24 horas, que comprende un sustrato, en donde el sustrato comprende una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato, y en donde dicho sustrato puede estar revestido con un revestimiento de liberación controlada; dicha preparación tiene una proporción de disolución específica in vitro. Reivindicación 1: Una preparación farmacéutica oral de liberación controlada adecuada para la dosificación cada 24 horas, que comprende un sustrato que contiene una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato; dicha preparación tiene una proporción de disolución in vitro medida usando el Método de Paleta de la Ph. Eur.(Ph. Eur. Paddle Method) a 75 rmp en 900 ml de buffer de fosfato 0,05 M a 37sC y utilizando HPLC: entre 15 y 35% de tramadol liberado después de 1 hora; entre 28 y 48% de tramadol liberado después de 2 horas; entre 47 y 67% de tramadol liberado después de 4 horas; entre 68 y 88% de tramadol liberado después de 8 horas; entre 79 y 99% de tramadol liberado después de 12 horas; entre 86 y 105% de tramadol liberado después de 24 horas; en peso, en donde dicha preparación suministra un efecto terapéutico durante aproximadamente 24 horas luego de la administración oral. Reivindicación 17: Un proceso para la elaboración de una preparación farmacéutica oral según se reivindica en las reivindicaciones 1 a 16, que comprende mezclar clorhidrato de tramadol y topiramato con un sustrato adecuado.
ARP030104634A 2002-12-13 2003-12-15 Preparaciones de liberacion controlada que comprenden tramadol y topiramato AR042472A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02080325 2002-12-13
EP03075123 2003-01-10

Publications (1)

Publication Number Publication Date
AR042472A1 true AR042472A1 (es) 2005-06-22

Family

ID=32598791

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104634A AR042472A1 (es) 2002-12-13 2003-12-15 Preparaciones de liberacion controlada que comprenden tramadol y topiramato

Country Status (15)

Country Link
US (1) US20060147527A1 (es)
EP (1) EP1572192A1 (es)
JP (1) JP2006514986A (es)
KR (1) KR20050075408A (es)
AR (1) AR042472A1 (es)
AU (1) AU2003296672A1 (es)
BR (1) BR0317177A (es)
CA (1) CA2506807A1 (es)
CL (1) CL2003002621A1 (es)
MX (1) MXPA05006210A (es)
MY (1) MY148475A (es)
PL (1) PL377351A1 (es)
RU (1) RU2005122008A (es)
TW (1) TW200427448A (es)
WO (1) WO2004054571A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
JP2008507508A (ja) 2004-07-22 2008-03-13 株式會社アモーレパシフィック トピラメート徐放性製剤及びその製造方法
CA2584338C (en) * 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
ATE552007T1 (de) 2005-08-26 2012-04-15 Univ Minnesota Dezellularisierung und rezellularisierung von organen und geweben
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
KR101971218B1 (ko) * 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) * 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP2328561B1 (en) * 2008-08-19 2015-11-25 Adcock Ingram Intellectual Property (Pty) Limited Rate Modulated Delivery of Drugs from a Three-Layer Tablet Comprising Tramadol, Diclofenac, Paracetamol
CA2746509C (en) 2008-12-19 2018-11-20 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of impulsive agression
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
AU2011235222B2 (en) 2010-03-31 2014-09-25 Supernus Pharmaceuticals Inc. Stabilized formulations of CNS compounds
EP2611472B1 (en) 2010-09-01 2016-02-10 Regents of the University of Minnesota Methods of recellularizing a tissue or organ for improved transplantability
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
RS60682B1 (sr) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US9290738B2 (en) 2012-06-13 2016-03-22 Miromatrix Medical Inc. Methods of decellularizing bone
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
KR20240104179A (ko) 2013-03-15 2024-07-04 미로매트릭스 메디칼 인크. 섬 세포 재세포화를 위한 관류 탈세포화된 간의 용도
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3509651B1 (en) 2016-09-06 2022-12-28 Miromatrix Medical Inc. Use of resected liver serum for whole liver engineering
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
JPH0474515A (ja) * 1990-07-13 1992-03-09 Toray Ind Inc 酸素吸収体
DK0566709T5 (da) * 1991-09-06 2009-05-18 Ortho Mcneil Janssen Pharm Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf
ATE145330T1 (de) * 1991-09-06 1996-12-15 Mcneilab Inc Zusammensetzungen, die tramadol und irgendein kodein, oxykoden oder hydrokoden enthalten, und deren verwendung
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
CA2381797C (en) * 1999-08-20 2008-04-15 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
CN1276953C (zh) * 2001-10-25 2006-09-27 旭化成化学株式会社 聚亚苯硫醚树脂组合物
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof

Also Published As

Publication number Publication date
AU2003296672A1 (en) 2004-07-09
CL2003002621A1 (es) 2005-03-11
JP2006514986A (ja) 2006-05-18
KR20050075408A (ko) 2005-07-20
BR0317177A (pt) 2005-10-25
EP1572192A1 (en) 2005-09-14
CA2506807A1 (en) 2004-07-01
RU2005122008A (ru) 2006-02-10
TW200427448A (en) 2004-12-16
MY148475A (en) 2013-04-30
WO2004054571A1 (en) 2004-07-01
US20060147527A1 (en) 2006-07-06
PL377351A1 (pl) 2006-01-23
MXPA05006210A (es) 2005-08-19

Similar Documents

Publication Publication Date Title
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
RU2005115855A (ru) Композиция трамадола продлонгированного высвобождением с 24-часовым действием
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
DK293087A (da) Fast dihydrocodeinpraeparat med reguleret afgivelse
AR065827A2 (es) Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina, composicion farmaceutica, procedimiento y preparacion y su uso en terapia
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
AR033688A1 (es) Composicion parenteral reconstituible
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
BR0212155A (pt) Composição farmacêutica
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
RS50058B (sr) Kompozicije oksikodona sa kontrolisanim oslobađanjem

Legal Events

Date Code Title Description
FA Abandonment or withdrawal